Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 7 de 7
Filtre
1.
An. bras. dermatol ; 94(6): 751-753, Nov.-Dec. 2019. graf
Article Dans Anglais | LILACS | ID: biblio-1054883

Résumé

Abstract Lobular capillary hemangioma or pyogenic granuloma is a benign vascular tumor of the skin or mucous membranes. Most patients present a single lesion. It manifests clinically as an erythematous, friable, and fast-growing tumor. This report details a case with exuberant presentation in a patient with ankylosing spondylitis, using adalimumab. Factors triggering pyogenic granuloma are not well known. They may spontaneously regress, but most require treatment.


Sujets)
Humains , Mâle , Adulte d'âge moyen , Maladies de la peau/anatomopathologie , Pelvispondylite rhumatismale/traitement médicamenteux , Granulome pyogénique/anatomopathologie , Antirhumatismaux/usage thérapeutique , Adalimumab/usage thérapeutique , Maladies de la peau/étiologie , Pelvispondylite rhumatismale/complications , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Granulome pyogénique/étiologie
3.
An. bras. dermatol ; 89(6,supl.1): 1-74, Nov-Dec/2014. tab, graf
Article Dans Anglais | LILACS | ID: lil-741059

Résumé

Brazil is a country of continental dimensions with a large heterogeneity of climates and massive mixing of the population. Almost the entire national territory is located between the Equator and the Tropic of Capricorn, and the Earth axial tilt to the south certainly makes Brazil one of the countries of the world with greater extent of land in proximity to the sun. The Brazilian coastline, where most of its population lives, is more than 8,500 km long. Due to geographic characteristics and cultural trends, Brazilians are among the peoples with the highest annual exposure to the sun. Epidemiological data show a continuing increase in the incidence of non-melanoma and melanoma skin cancers. Photoprotection can be understood as a set of measures aimed at reducing sun exposure and at preventing the development of acute and chronic actinic damage. Due to the peculiarities of Brazilian territory and culture, it would not be advisable to replicate the concepts of photoprotection from other developed countries, places with completely different climates and populations. Thus the Brazilian Society of Dermatology has developed the Brazilian Consensus on Photoprotection, the first official document on photoprotection developed in Brazil for Brazilians, with recommendations on matters involving photoprotection.


Sujets)
Humains , Radioprotection/méthodes , Coup de soleil/prévention et contrôle , Produits antisolaires/administration et posologie , Maladies de la peau/prévention et contrôle , Tumeurs cutanées/prévention et contrôle , Tumeurs cutanées/épidémiologie , Énergie solaire/statistiques et données numériques , Coup de soleil/épidémiologie , Produits antisolaires/composition chimique , Rayons ultraviolets/effets indésirables , Vitamine D/métabolisme , Brésil/épidémiologie , Vêtements , Exposition environnementale , Rayonnements électromagnétiques , Promotion de la santé/méthodes , Concepts météorologiques
4.
An. bras. dermatol ; 89(3): 436-440, May-Jun/2014. tab
Article Dans Anglais | LILACS | ID: lil-711603

Résumé

BACKGROUND: Psoriasis is a chronic immune-mediated disease, characterized by increased levels of TNFα. Anti-TNFα agents have revolutionized the treatment of severe psoriasis by targeting an important molecule involved in its pathogenesis. OBJECTIVES: We report the experience of a state referral center that uses anti-TNFα agents for psoriasis. METHODS: We conducted a retrospective case series. Seventy-four out of 120 patients met the inclusion criteria. Clinical and laboratory data was analyzed using the chi-squared, Wicoxon and McNemar's tests. Associations were considered statistically significant when p-value<0.05. RESULTS: Forty-one subjects (55.40%) were male, with a mean age of 47.69±14.99 years. Median disease duration and pre-treatment PASI were 14.0 months (IQR 9.0-20.0), and 13.55 points (IQR 8.5-20.32). Sixty patients (81.10%) had arthropathic psoriasis. Forty-six subjects (62.20%) had comorbidities; the most frequent was dyslipidemia (25.70%). In 55.40% of patients, insufficient response to conventional therapies was the principal indication for using anti-TNFα drugs. Clinical improvement occurred in 93.20% of cases, and the post-treatment PASI median was 0.0 points (IQR 0.0-0.0). Adverse effects occurred in 6.80% of patients. Infections and elevation of transaminases occurred in 28.40% and 8.10% of cases, respectively. CONCLUSION: Post-treatment reduction in PASI was satisfactory and the occurrence of adverse effects was minor, mostly mild infusion effects and local reactions at drug administration sites. .


Sujets)
Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Anti-inflammatoires/usage thérapeutique , Psoriasis/traitement médicamenteux , Facteur de nécrose tumorale alpha/antagonistes et inhibiteurs , Anticorps monoclonaux humanisés/usage thérapeutique , Anticorps monoclonaux/usage thérapeutique , Immunoglobuline G/usage thérapeutique , Facteurs immunologiques/usage thérapeutique , Études rétrospectives , Récepteurs aux facteurs de nécrose tumorale/usage thérapeutique , Facteurs temps , Résultat thérapeutique
5.
An. bras. dermatol ; 88(3): 473-475, jun. 2013. tab, graf
Article Dans Anglais | LILACS | ID: lil-676248

Résumé

Congenital Hypertrichosis Lanugionsa is a rare autosomal dominant genetic disorder, with fewer than 50 cases reported in the literature. It is characterized by excessive lanugo hair, sparing only the mucous membranes, palms and soles. It may be associated with other organic abnormalities and should form part of the dermatologist's current knowledge. We discuss some aspects of the syndrome in question arising from the case report of a 2-year-old female patient, black, with classic clinical presentation, with no other associated congenital abnormalities.


A hipertricose Lanugionsa Congênita é uma desordem genética rara, autossômica dominante, com menos de 50 casos descritos na literatura. É caracterizada por pêlo lanugo excessivo, poupando apenas membranas mucosas, palmas e plantas. Pode estar associada a outras anormalidades orgânicas, devendo ser de conhecimento do dermatologista. Discutiremos aspectos da síndrome em questão a partir do relato de caso de uma paciente do sexo feminino, negra, 02 anos, com apresentação clínica clássica, sem outras anormalidades congênitas associadas.


Sujets)
Enfant d'âge préscolaire , Femelle , Humains , Hypertrichose/congénital , Diagnostic différentiel , Hypertrichose/diagnostic , Hypertrichose/génétique , Syndrome , Malformations dentaires
6.
An. bras. dermatol ; 88(2): 185-198, abr. 2013. tab, graf
Article Dans Anglais | LILACS | ID: lil-674167

Résumé

Inherited epidermolysis bullosa (EB) is a heterogeneous group of genetic disorders that present with skin and, in some cases, mucosal fragility, predisposing patients to the development of blisters and/or erosions after minimal trauma or friction. Children with a recurrent history of these kinds of lesions or neonates that present them in the absence of another reasonable explanation should be investigated. Diagnosis must be based on clinical and histopathological findings. To date, management of inherited EB basically consists in avoiding traumas that trigger lesions, as well as preventing infection and facilitating healing of the wounds with the systematic use of bandages.


A epidermólise bolhosa hereditária (EBH) compreende um grupo heterogêneo de desordens genéticas que têm em comum a fragilidade cutânea e, em alguns casos mucosa, predispondo ao desenvolvimento de bolhas e/ou erosões após fricção ou trauma mínimo. Crianças com história recorrente deste tipo de lesão ou neonatos que as apresentem na ausência de outra explicação plausível devem ser investigados. O diagnóstico deve se basear em achados clínicos e histopatológicos. Até o presente momento, o manejo da EBH consiste basicamente em evitar os traumas desencadeadores das lesões, bem como evitar a infecção e facilitar a cicatrização das feridas com o uso sistemático de curativos.


Sujets)
Humains , Épidermolyse bulleuse , Bandages , Épidermolyse bulleuse/classification , Épidermolyse bulleuse/génétique , Épidermolyse bulleuse/anatomopathologie , Épidermolyse bulleuse/thérapie , Peau/anatomopathologie , Cicatrisation de plaie
7.
An. bras. dermatol ; 86(4,supl.1): 144-147, jul,-ago. 2011. ilus
Article Dans Portugais | LILACS | ID: lil-604145

Résumé

A psoríase acomete 0,12 por cento a 0,71 por cento da população infantil, sendo que a forma eritrodérmica, grave e rara, ocorre em menos de 1,5 por cento dos casos. Os antagonistas do Fator de Necrose Tumoral-α (TNFα) constituem nova classe de drogas, utilizada para tratamento da psoríase grave a moderada, refratária às terapias convencionais. O Etanercepte é uma proteína de fusão do receptor do TNF-α, aprovada pelo Food and Drug Administration para tratamento da artrite reumatoide juvenil no grupo infantil. Apresentamos um caso de criança com 7 anos de idade, com psoríase em placa desde 8 meses de vida, que evoluiu para eritrodermia refratária a ciclosporina e metotrexato, com excelente resposta ao etanercepte, sem feitos adversos.


Psoriasis affects 0.12 percent to 0.71 percent of all children. Erythrodermic psoriasis is an uncommon but serious disorder, occurring in less than 1.5 percent of cases. Tumor necrosis factor-alpha blockers (TNF-α) are a new class of drugs used to treat moderate to severe psoriasis refractory to conventional therapies. Etanercept is a TNFα receptor fusion protein, approved by the FDA for treating juvenile rheumatoid arthritis. We present the case of a 7-year-old suffering from plaque psoriasis since 8 months old which evolved into erythroderma refractory to cyclosporine and methotrexate. Patient responded excellently to etanercept, with no adverse side effects.


Sujets)
Enfant , Femelle , Humains , Dermatite exfoliatrice/traitement médicamenteux , Immunoglobuline G/usage thérapeutique , Immunosuppresseurs/usage thérapeutique , Méthotrexate/usage thérapeutique , Psoriasis/traitement médicamenteux , Récepteurs aux facteurs de nécrose tumorale/usage thérapeutique , Association de médicaments/méthodes
SÉLECTION CITATIONS
Détails de la recherche